PROCEPT BioRobotics has announced it now has five AquaBeam Robotic Systems installed across all of Northside Health Systems’ state-of-the-art surgical facilities.
“I am thrilled that Northside is expanding their top-ranked surgical robotics program to now include Aquablation therapy at all five of their hospitals,” stated Lewis S. Kriteman, M.D., F.A.C.S. partner at Georgia Urology. “As the first surgeon in Georgia to perform Aquablation therapy, I applaud and thank Northside for leading the way in providing innovative surgical techniques to surgeons and expanding access for patients. Aquablation therapy provides patients a safe and effective BPH treatment option, regardless of prostate size or shape. I believe Aquablation therapy is an attractive procedure for patients who have yet to seek treatment for their BPH symptoms as well as those who are not satisfied with the results from current surgical or medical options available to treat BPH.”
“PROCEPT is proud to partner with leading health systems, such as Northside, that are committed to advancing patient care through next-generation innovations and we look forward to supporting their growing programs throughout the greater Atlanta area,” said Sham Shiblaq, Executive Vice President, Chief Commercial Officer of PROCEPT. “As we continue to expand our global commercial footprint, our dedicated team remains focused on accelerating adoption of Aquablation therapy and bringing this much needed treatment option to all patients.”
Aquablation therapy combines real-time, multi-dimensional imaging, automated robotics, and heat-free waterjet ablation for targeted, controlled, and immediate removal of prostate tissue. Combining both cystoscopic visualization and ultrasound imaging, surgeons can create a personalized treatment plan tailored to each patient’s anatomy. Once the personalized treatment map is complete, the robotically controlled, heat-free waterjet ablates the prostate tissue, avoiding critical structures to preserve sexual function and continence.1,2,3
1Gilling P. et al. Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial. Can J Urol. 2020 Feb;27(1):10072-10079.
2Desai M, et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results. Canadian Journal of Urology. 27(2):10147-10153. Apr 2020.
3Bach T. et al. First Multi-Center All-Comers Study for the Aquablation Procedure. J Clin Med. 2020 Feb;9(2): 603.
Source: PROCEPT BioRobotics.